Effect of glucagon-like-peptide-1 (GLP-1) on left ventricular function during percutaneous coronary intervention (PCI)

Investigation of the effect of glucagon-like-peptide-1 (GLP-1) on left ventricular function during elective coronary angioplasty and stenting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN77442023

Enrollment

Registered

2010-04-23

Start date

2009-05-22

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Cardiovascular

Interventions

Assessment of left ventricular function during coronary angioplasty. In the active arm patients will receive an intravenous infusion of glucagon-like peptide-1 at 1.2 pmol/kg/min which will start afte

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age over 18 (male or female and no upper age limit) 2. Able to give informed consent 3. On the waiting list for elective PCI to a single vessel coronary stenosis 4. Normal left ventricular function

Exclusion criteria

Exclusion criteria: 1. Atrial fibrillation 2. Myocardial infarction less than 3 months previously 3. Previous coronary artery bypass grafts 4. Treatment with insulin, sitagliptin, vildagliptin or exenatide

Design outcomes

Primary

Measure	Time frame
Left ventricular function with and without GLP-1, measured during two balloon inflations in the coronary artery which are 30 minutes apart	—

Secondary

Measure	Time frame
1. Collateral flow with and without GLP-1 2. Troponin I at 24 hours Measured during two balloon inflations in the coronary artery which are 30 minutes apart.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 5, 2026